# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹736 Cr** Q4 FY26 (+22% QoQ) · **₹2,542 Cr** FY26 (-1% YoY) * **Volume Growth:** **15%** QoQ · **14%** YoY (Q4) · **-4%** YoY (Full Year) * **EBITDA:** **₹169 Cr** Q4 (+64% QoQ) · **₹567 Cr** FY26 * **EBITDA Margin:** **23%** Q4 · **22%** FY26 * **PAT:** **₹82 Cr** Q4 · **₹330 Cr** FY26 (incl. **₹81 Cr** tax benefit) * **Leverage:** **₹508 Cr** Net Debt · **0.9x** Net Debt/EBITDA ## B. Revenue and Volume * **Record Quarterly Performance:** Achieved highest-ever quarterly top-line results in Q4, driven by a sharp demand recovery starting mid-November. * **Operational Recovery:** Plant utilization surpassed **80%** in the final quarter, reversing earlier headwinds caused by an 8-year maintenance cycle and monsoon disruptions. * **Geographic Mix:** Revenue remains heavily domestic-centric, with exports to Europe accounting for only **4% to 5%** of total volumes. ## C. Margins and Profitability * **Margin Normalization:** Profitability recovered to historical ranges due to asset sweating and stabilized input costs, supported by price hikes implemented in **March**. * **Adjusted Earnings:** Full-year bottom-line performance was bolstered by a one-time deferred tax credit; excluding this, core PAT saw a year-on-year decline. * **Capital Efficiency:** Reported ROCE stood at 16%, though underlying efficiency improves to **17%** when adjusting for significant capital work in progress. ## D. Debt and Finance Costs * **Currency Headwinds:** Finance costs surged **35%** YoY, significantly exceeding guidance due to mark-to-market (MTM) losses on FX swaps and unexpected INR depreciation. * **Balance Sheet Health:** Despite rising interest costs, the company maintains a conservative leverage profile with a net debt to EBITDA ratio below 1.0x. ## E. Cash Flow and Capex * **Self-Funded Growth:** Operations generated **INR 436 Cr** in cash, more than sufficient to cover the **INR 394 Cr** deployed toward ongoing capital expenditure. --- # 2. Manufacturing & Capacity ## A. Key Figures * **Caustic Soda Utilization:** **78%–85%** Q4 range (vs. 67%–70% prior) * Segment Utilization: 75% CPVC & 80% ECH by FY28 * **Captive Chlorine Consumption:** **~75%** Current * **Renewable Energy Share:** **8% to 9%** Current ## B. Plant Utilization Levels * **Operational Recovery:** Caustic soda assets returned to optimum levels following major maintenance in Q3, successfully mitigating previous headwinds from utilization gaps and price volatility. * **Long-term Utilization Targets:** Management aims for optimum utilization of **70% to 75%** for Chlorotoluene by **FY 2028**, while CPVC and ECH are already performing near their respective steady-state benchmarks. ## C. Capacity Expansion Projects * **Strategic Scaling:** Projects for ECH and CPVC remain on schedule and within budget; the company is currently **doubling production capacity** for both, with commissioning slated for **Q2 FY27**. * **New Commissioning:** A new CPVC facility was commissioned in **March 2026**, enhancing immediate production capabilities to capture projected double-digit market growth. * **Asset Strategy:** No current plans to expand caustic soda capacity, as the focus remains on downstream integration, though future expansion remains a strategic lever if demand warrants. ## D. Renewable Energy Integration * **Green Energy Ramp-up:** Share of wind and solar power is projected to nearly double to **15%** following the addition of **19.50 MW** of wind-solar hybrid capacity. * **Regulatory Advantage:** The company is leveraging Gujarat-specific government schemes to optimize power costs through a wind-solar hybrid plant model. ## E. Captive Chlorine Consumption * **Value Chain Integration:** Captive consumption of chlorine is targeted to reach **90%–95% by FY28**, driven by the ramp-up of new facilities and increased supply to pipeline customers. --- # 3. Product & Segment Performance ## A. Key Figures * **Derivatives & Specialty Revenue Mix:** **54%** Q4 contribution (vs. 52% Q3) * **Product Basket Split:** **60%** Basic Chemicals · **40%** Specialty Products ## B. Derivatives and Specialty * **Revenue Mix Shift:** The derivatives and specialty business continues to expand its share of the total portfolio, reaching a new quarterly high. * **Segment Dynamics:** Basic chemicals maintain resilient demand despite pricing pressure, while the specialty segment faces volume constraints due to elevated cost structures. * **End-Market Exposure:** The Chlorotoluene line is strategically positioned to serve high-value agrochemical and pharmaceutical specialty chemical manufacturers. ## C. Chlorotoluene Ramp-up * **Phased Commercialization:** Following the **March 2025** commissioning, revenue is scaling monthly as the company navigates rigorous customer approval cycles. * **Medium-Term Outlook:** Management projects a significant top-line contribution by **FY 2027**, characterized by a steady volume ramp-up rather than immediate peak utilization. * **Geopolitical Headwinds:** While demand improved in early 2026, recent war-related uncertainties have caused a temporary volume dip; however, a recovery is anticipated starting in **May**. ## D. CPVC and ECH Recovery * **Cyclical Demand Rebound:** CPVC raw material demand has seen a sustained recovery since **mid-November**, successfully reversing the seasonal slowdown observed during the monsoon period. --- # 4. Demand & Pricing Trends ## A. Key Figures * **ECU Realization:** **₹30,000** Q4 FY26 · **₹37,000** Current Range * **Caustic Soda Price Growth:** **30% to 35%** Geopolitical surge * **Derivative Price Growth:** **~50%** Chloromethanes and other products ## B. ECU & Pricing Dynamics * **Lagged Pricing Impact:** Q4 results saw stable realizations as orders were pre-booked; the full benefit of geopolitical price escalations is deferred to **Q1 FY27**. * **Gradual Normalization:** While caustic soda prices have cooled slightly from recent peaks, management expects pricing adjustments to be slow as global shipping and facilities stabilize post-conflict. * **Product-Specific Trends:** ECH realizations saw marginal sequential improvement, while CPVC pricing remains volatile and closely tethered to PVC market movements. ## C. Raw Material & Margin Protection * **Cost Pass-through:** Realizations for chemical derivatives are being adjusted upward in alignment with raw material inflation to maintain spreads. * **Inventory De-risking:** Management has shifted to a cautious procurement stance to mitigate the risk of high-cost inventory losses amidst fluctuating market prices. ## D. Domestic Volume Recovery * **Short-term Volume Pressure:** Domestic volumes in **April** softened as both the company and its Tier-1 customers exercised caution regarding high inventory carrying costs. --- # 5. Strategic Initiatives ## A. Greenfield Project Evaluation * **Long-term Capacity Planning:** Management is conducting due diligence on a new site to secure growth runways for **FY29 and FY30**. * **Capex Announcement Timeline:** Following the historical strategy of initiating new projects as current ones mature, a formal expansion announcement is expected **within the current year**. ## B. Portfolio Diversification * **Resilience Through Mix:** A diversified multi-product portfolio is being leveraged to hedge against segment-specific headwinds and stabilize the growth trajectory. * **R&D and Chemistry Focus:** While new chemistries are under internal review, the company clarified that no specific "green chemistry" projects are currently in the pipeline. ## C. Customer Approval Progress * **Chlorotoluene Ramp-up Delay:** The Chlorotoluene plant underwent an extensive **seven to eight month** customer approval and testing cycle, limiting its volume contribution for **FY26**. --- # 6. Risks & Chemical Industry Factors ## A. Key Figures * **Sales Volume:** **4%** degrowth in FY 2026 * **Energy Costs:** **~15%** increase due to geopolitical impacts * **Currency Depreciation:** **2% to 3%** historical average (threshold for minimal MTM impact) ## B. Geopolitical & Supply Chain Dynamics * **Supply Chain Fragility:** Global disruptions in raw materials and shipping are expected to persist for **4-5 months** post-de-escalation; current constraints in ethylene are limiting PVC plant utilization. * **Trade Policy Tailwinds:** The Indian export sector is benefiting from structural shifts, including **reduced US reciprocal tariffs** and the **removal of Chinese VAT export rebates**. * **Pricing Volatility:** Conflict-driven escalations in West Asia have inflated both raw material and finished good prices, posing a potential risk to long-term market demand. ## C. Currency & Financial Impact * **Interest Expense Headwinds:** Despite debt reduction, interest costs rose as INR depreciation exceeded historical norms. * **MTM Mitigation:** Finance teams are actively seeking strategies to hedge against currency volatility to protect the bottom line from future mark-to-market hits. ## D. Input Costs & Seasonality * **Inflationary Lag:** Management expects recent spikes in raw material and finished good costs to manifest more significantly in upcoming reporting periods. * **Seasonal Demand Fluctuations:** Recent volume contraction was driven by monsoon-related softness in ECH and CPVC; management emphasizes **annualized performance evaluation** over QoQ metrics due to these cyclical patterns. * **FY27 Recovery Outlook:** Anticipated stabilization in PVC pricing and the passing of seasonal Q1/Q2 demand troughs are expected to drive improved performance in the next fiscal year. --- # 7. Guidance & Outlook ## A. Key Figures * **FY27 Volume Growth Target:** **10% to 12%** * **Chlorotoluene Utilization (FY27):** **~40%** projected ## B. FY27 Volume Targets * **Growth Acceleration:** Management expects next fiscal to outperform current levels, with Q4 serving as the "new normal" for operational run-rates. * **Regulatory & Market Tailwinds:** Anticipated volume recovery is supported by clarity on **Anti-Dumping Duties (ADD)**, **BIS regulations**, and a post-election rebound in the real estate sector. * **Product Mix Shift:** Growth strategy focuses on transitioning volumes toward higher-value segments to drive disproportionate value appreciation. * **Timeline & Risk Factors:** Volume momentum is expected to pick up starting **May 2026**, though outlook remains contingent on stable geopolitical conditions. ## C. Commissioning & Utilization * **Capacity Expansion:** New ECH and CPVC facilities are slated for commissioning in **Q2 FY27**, following a gradual ramp-up trajectory. * **Long-term Utilization:** While initial utilization for new assets will be modest, management targets optimum utilization levels by **FY28**.